Clinical Trial Update: Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 neoadjuvant trial of dabrafenib plus trametinib for AJCC Stage IIIB-C BRAF V600 mutation-positive melanoma; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Tafinlar) (dabrafenib)
• Trametinib (Mekinist) (trametinib)

Snippet

Sponsor: Melanoma Institute Australia | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING